The synergistic effect of the triglyceride-glucose index and a body shape index on cardiovascular mortality: the construction of a novel cardiovascular risk marker
Authors' conclusion
The simultaneous assessment of the TyG index and ABSI revealed a synergistic effect on cardiovascular mortality. We recommended the use of TyG-ABSI instead of the TyG index and other modified TyG indices in cardiovascular risk assessment.
Study context
- Population
- Individuals from the National Health and Nutrition Examination Survey (NHANES) 2001–2018
- Participants
- 17,329 individuals
- Exposure
- High triglyceride-glucose (TyG) and high a body shape index (ABSI) vs other TyG/ABSI combinations; TyG-ABSI vs TyG index and modified TyG indices
- Outcome
- Cardiovascular mortality
- Follow-up
- Median 8.92 years
Methodological detailsNHANES 2001-2018, Cox regression, restricted cubic splines, ROC analysis, mediation analysis
- NHANES 2001-2018
- Cox regression
- Restricted cubic splines
- ROC analysis
- Mediation analysis
Main finding
As reported in the abstract
Cardiovascular mortality, high TyG and high ABSI
HR, individuals with diabetes
1.714
95% CI 1.123–2.616
HR, individuals without diabetes
1.402
95% CI 1.003–1.960
Observational data: associations, not effects.
Further findings
| Outcome | Values | P value |
|---|---|---|
| Predictive value for cardiovascular mortality (Harrell's C-index)TyG-ABSI vs each other TyG index | TyG-ABSI 0.710 · TyG index 0.623 · TyG-BMI 0.539 · TyG-WC 0.612 · TyG-WHtR 0.622 | all p < 0.001 |
Cardiovascular deaths · median follow-up 8.92 years
- Cardiovascular deaths
- 673 (3.9%)
Shape of TyG-ABSI association with cardiovascular mortality
- J-shaped relationship in individuals with diabetes; positive linear relationship in individuals without diabetes
Mediation by arterial stiffness (estimated pulse wave velocity) of TyG-ABSI effect
- Mediation proportion
- 42.7%
Original publication
The synergistic effect of the triglyceride-glucose index and a body shape index on cardiovascular mortality: the construction of a novel cardiovascular risk marker. Cardiovasc Diabetol. Published 7 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →